Acute myeloid leukemia, FLT3 internal tandem duplication
MONDO:0100415Any acute myeloid leukemia that has the chromosomal anomaly FLT3 internal tandem duplication. (A genetic abnormality that arises from duplications of the juxtamembrane portion of the gene and results in constitutive activation of the FLT3 receptor tyrosine kinase protein in early hematopoietic progenitor cells. It is associated with acute myelogenous leukemia where it appears to correlate with a poor prognosis.)
Also known as: AML, Activating FLT3-ITD Gene Mutation, AML, Activating FLT3-ITD Mutation, AML, FLT3 ITD, AML, FLT3 internal tandem duplication, AML, FLT3-ITD, AML, FLT3-ITD Activating Mutation, AML, FLT3-ITD Mutation, AML, FLT3/ITD Mutation
3109 clinical trials for this condition and its sub-types, 18 tagged with Acute myeloid leukemia, FLT3 internal tandem duplication itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New triple therapy targets FLT3-Mutated leukemia in frail patients
Disease control OngoingThis study tests a combination of three drugs—gilteritinib, venetoclax, and azacitidine—in people newly diagnosed with a fast-growing form of acute myeloid leukemia (AML) that has a FLT3 gene change. Participants are older or have other health issues that prevent them from receiv…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo therapy shows promise for kids with aggressive leukemia
Disease control OngoingThis study tests whether adding the drug midostaurin to standard chemotherapy helps children with a certain genetic type of acute myeloid leukemia (FLT3-mutated AML). About 22 children will receive the drug twice daily alongside chemo, then continue midostaurin alone for 12 more …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for kids with relapsed AML: targeted drug combo trial opens
Disease control OngoingThis study tests an experimental drug called quizartinib, given with chemotherapy, for children and young adults (ages 1 month to 21 years) whose acute myeloid leukemia (AML) has returned or not responded to treatment. The goal is to see if the combination is safe and can help co…
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo targets tough leukemia in early trial
Disease control OngoingThis study tests a new combination of two drugs (gemtuzumab ozogamicin and gilteritinib) for adults with a specific genetic form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial aims to see if the combination is safe and helps control th…
Phase 2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC